We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
-9.21%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$617M
AUM Growth
-$114M
Cap. Flow
-$1.09M
Cap. Flow %
-0.18%
Top 10 Hldgs %
74.33%
Holding
32
New
6
Increased
3
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$9.05M
2
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$7.74M
3
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$6.69M
4
ALT icon
Altimmune
ALT
+$5.59M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$4.66M

Top Sells

Rank Stock Value
1
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$13.7M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$7.64M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$6.53M
4
CVRX icon
CVRx
CVRX
+$6.52M
5
AKYA
Akoya BioSciences
AKYA
+$6.12M

Sector Composition

Rank Sector Weight
1 Healthcare 95.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$726M
$78.7M 12.75%
4,563,962
– –
TIL icon
2
Instil Bio
TIL
$48.3M
$73.8M 11.96%
343,254
– –
RLMD icon
3
Relmada Therapeutics
RLMD
$557M
$61.3M 9.93%
2,270,072
– –
TVTX icon
4
Travere Therapeutics
TVTX
$5.2B
$51.4M 8.33%
1,994,997
– –
GHRS icon
5
GH Research
GHRS
$1.93B
$37.5M 6.08%
2,051,060
+29,075
+1% +$513K
TCDA
6
DELISTED
Tricida, Inc. Common Stock
TCDA
$36.9M 5.99%
4,494,851
+1,000,000
+29% +$9.05M
VRDN icon
7
Viridian Therapeutics
VRDN
$2.09B
$34.3M 5.55%
1,852,919
– –
MRNS
8
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$29.5M 4.78%
3,156,803
+276,707
+10% +$2.75M
CLDX icon
9
Celldex Therapeutics
CLDX
$2.99B
$29.5M 4.77%
865,116
– –
WHWK
10
Whitehawk Therapeutics
WHWK
$190M
$26M 4.2%
1,529,402
– –
KDNY
11
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$21M 3.4%
1,283,821
– –
LIAN
12
DELISTED
LianBio American Depositary Shares
LIAN
$20M 3.23%
5,378,341
– –
VTGN icon
13
VistaGen Therapeutics
VTGN
$9.89M
$19.9M 3.22%
534,910
– –
LONA
14
LeonaBio Inc
LONA
$66.3M
$13.5M 2.19%
100,000
– –
EIGR
15
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$12.2M 1.98%
+48,992
New +$7.74M
NUVL
16
DELISTED
Nuvalent
NUVL
$11.2M 1.81%
803,951
– –
LENZ
17
LENZ Therapeutics
LENZ
$166M
$8.22M 1.33%
230,374
– –
PRVB
18
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$8.19M 1.33%
+1,118,653
New +$6.69M
COGT icon
19
Cogent Biosciences
COGT
$6.65B
$8.15M 1.32%
1,088,817
– –
ATYR
20
aTyr Pharma
ATYR
$47.6M
$7.48M 1.21%
1,398,889
-166,111
-11% -$941K
AFMD
21
DELISTED
Affimed
AFMD
$6.24M 1.01%
142,857
– –
SRRA
22
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$5.21M 0.84%
+162,479
New +$4.66M
ALT icon
23
Altimmune
ALT
$552M
$4.63M 0.75%
+759,719
New +$5.59M
CNTA
24
DELISTED
Centessa Pharmaceuticals
CNTA
$3.69M 0.6%
411,361
-715,911
-64% -$6.53M
ATXS
25
DELISTED
Astria Therapeutics
ATXS
$3.62M 0.59%
538,999
– –
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q1 2022 Portfolio in Review

As of Q1 2022, VR Adviser held 32 positions worth $617M, down 16% from $732M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

VR Adviser's Q1 2022 filing shows 6 new, 3 increased, 2 reduced and 5 closed positions. Its largest new stake was Eiger BioPharmaceuticals, Inc.: 48,992 shares worth $12.2M. The largest sale was Kinnate Biopharma Inc. Common Stock, an estimated $13.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier.

  • VR Adviser's largest Q1 2022 buy was Eiger BioPharmaceuticals, Inc.: 48,992 shares worth $12.2M.
  • VR Adviser added most to Tricida, Inc. Common Stock in Q1 2022, an estimated $9.05M increase.
  • VR Adviser's biggest Q1 2022 reduction was Centessa Pharmaceuticals, cutting an estimated $6.53M.
  • VR Adviser fully exited Kinnate Biopharma Inc. Common Stock in Q1 2022, selling an estimated $13.7M.
  • VR Adviser's ten largest holdings make up 74% of its $617M portfolio in Q1 2022.
  • VR Adviser opened 6 new positions and closed 5 in Q1 2022.
  • VR Adviser's portfolio value fell 16% quarter-over-quarter to $617M.

Based on VR Adviser's 13F filing for Q1 2022, filed 16 May 2022.